The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) — WB-LuPSMA  

Metastatic Castration Resistant Prostate Cancer (mCRPC) Clinical Trial

Official title: The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lu-PSMA

Status Terminated

Clinical Trial Summary

The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA

Clinical Trial Description

Multicentric, observational, single arm, prospective, study.

All patients will undergo imaging assessments according to clinical practice or to Lu-PSMA Tumor Institute of Romagna (IRST) 185.03 protocol, as follows:

• Baseline, before the treatment with Lu-PSMA, CT and WB-MRI will be performed

• At the end of treatment with Lu-PSMA, CT and WB-MRI will be performed

• In post-treatment follow-up every 4 months, until progression or for 1 year, CT and WB-MRI will be performed.

Patients participating in this observational study will not be subjected to any additional procedure that falls outside the clinical practice or the study 185.03 Lu-PSMA trial at IRST. ;

Related Conditions & MeSH terms

• Metastatic Castration Resistant Prostate Cancer (mCRPC)
• Prostatic Neoplasms

• NCT number: NCT05208229
• Study type: Observational
• Source: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
• Status: Terminated
• Start date: October 25, 2022
• Completion date: October 25, 2022